2,5-Dimethoxy-4-tert-butylamphetamine


2,5-Dimethoxy-4-tert-butylamphetamine is a non-hallucinogenic serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families.

Use and effects

According to Alexander Shulgin and colleagues, DOTB has been found to be inactive in humans at oral doses of up to 25mg.

Pharmacology

Pharmacodynamics

DOTB binds with high affinity to the serotonin 5-HT2 receptors, including to the serotonin 5-HT2A and 5-HT2C receptors and, to about a 10-fold lesser extent, to the serotonin 5-HT2B receptor. It has been found to act as a partial agonist of the serotonin 5-HT2A receptor, with an intrinsic efficacy of about 30% for phosphatidylinositol hydrolysis and about half of the efficacy of (R)-DOB. DOTB has also been assessed and found to act as a partial agonist of the serotonin 5-HT2B receptor.
The drug appeared to be inactive in animals in the conditioned avoidance test in rodents. DOTB only partially substituted for DOM in rodent drug discrimination tests and with much lower potency than other DOx drugs. In combination with DOM, DOTB produced some antagonism of the stimulus generalization of DOM, suggesting action as a lower-efficacy partial agonist of the serotonin 5-HT2A receptor. Unlike DOM but similarly to DOAM, DOTB did not substitute for 5-MeO-DMT in rodent drug discrimination tests. It also did not affect locomotor activity in rodents, again in contrast to other DOx drugs, though there were non-significant increases in locomotion at the highest assessed doses. It did still produce hyperthermia in rabbits similarly to other DOx drugs, albeit with dramatically reduced potency.

Chemistry

DOTB is part of the series of straight-chain and branched-chain 4-alkylated DOx drugs that also includes DOM, DOET, DOPR, DOBU, DOAM, and DOHx, among others.
Some other notable analogues of DOTB include DOBU, DOIB, and DOSB.
[Image:DOIB,DOSBandDOTB.png|540px|thumb|left|class=skin-invert-image|DOIB, DOSB, and DOTB.]

History

DOTB was first described in the scientific literature by 1974. Its psychoactive effects were first assessed and described by Alexander Shulgin in 1975.

Society and culture

Legal status

Canada

DOTB is a controlled substance in Canada under phenethylamine blanket-ban language.